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Invasive pneumococcal diseaseSerotypes/genotypes causing invasive pneumococcal disease (IPD) in adults are determined by vaccina-
tion strategies. The aim of this study was to assess the epidemiology of IPD in adults (18 years) after
PCV13 introduction for children: serotypes, clonal complexes, antibiotic non-susceptibility and clinical
presentations.
We performed a prospective, clinical surveillance of hospitalized culture-confirmed IPDs in adults in
nine Spanish hospitals (August 2010–June 2015). A total of 1087 culture-confirmed IPD episodes were
included, of which 772 (71.0%) had bacteremic pneumonia (401 complicated/371 uncomplicated pneu-
monia), 122 (11.2%) meningitis, 102 (9.4%) non-focal bacteremia, 34 (3.1%) peritonitis and 57 (5.3%)
others. The most common serotypes were: 3 (12.7%), 19A (8.5%), 8 (7.7%), 7F (6.3%), 1 (4.2%), 6C
(4.2%), 11A (4.2%), 22F (4.2%) and 14 (4.0%). Vaccine types (PCV13 + 6C) caused 49.8% of IPD episodes,
with a significant decrease over the 5-year period, and significant decreases in serotypes 6C and 7F.
The most common genotypes were: CC180 (8.4%), CC191 (6.0%), and CC53 (5.0%).
Vaccine types caused 53.9% (414/768) pneumonia episodes and 58.9% (235/399) complicated pneumo-
nia, 53.4% IPD in adults <50 years (143/268), and 54.7% IPD in immunocompetent patients (337/616).
Overall non-susceptibility was 25.9% to penicillin (1.1% for parenteral criteria), 24.9% to erythromycin
and 2.7% to levofloxacin.
Conclusions: Although the percentage of vaccine-types causing IPDs in adults significantly decreased, it
remained high. Associations of vaccine types with pneumonia (with complicated pneumonia for specific
serotypes), and immunocompetent patients point to the burden of IPD caused by PCV13 serotypes.
 2018 Elsevier Ltd. All rights reserved.1. Introduction
Streptococcus pneumoniae is a major human pathogen causing
pneumonia, meningitis and other invasive diseases. The capsular
polysaccharide is the main pneumococcal virulence factor thatin: A 5-
2 A. Fenoll et al. / Vaccine xxx (xxxx) xxxhas been associated with differences in the ability of S. pneumoniae
strains to colonize the nasopharynx and cause invasive disease, as
well as variations in disease manifestation, population groups
affected, antimicrobial resistance and geographical distribution
[1]. Moreover, due to the plasticity of its genome, S. pneumoniae
is able to respond to human interventions such as antibiotic treat-
ment and vaccination for disease prevention. Serotype replace-
ment can occur through expansion of existing serotypes/clones,
emergence of new clones expressing non-vaccine serotypes or cap-
sular switching [2]. This opens the question as to whether the
genetic background (defined by lineages) has a role in clinical/epi-
demiological characteristics classically associated with capsules.
Molecular typing, in addition to capsular serotyping, might provide
valuable information on evolutionary changes and subsequent
clinical consequences.
Soon after the introduction of the 7-valent pneumococcal con-
jugate vaccine (PCV7) and subsequent 13-valent PCV (PCV13) in
childhood immunization programs, significant and progressive
reductions were reported in the incidence of invasive pneumococ-
cal disease (IPD) in children and adults [3–6], due, in the latter, to
the herd effect [7–9]. Nevertheless, the higher incidence rates of
IPD remain in older adults and children younger than 5.
Geographic serotype distribution is variable and partly condi-
tioned by antimicrobial consumption and vaccine strategies. In
Spain, PCV13 was introduced in June 2010 for immunization of
healthy children but, in contrast to most European countries, it
was not included into the universal immunization programmFig. 1. Regional infant vaccination during the study period (2010–2015) and distribut
hospitals. Green indicates regions where PCV13 was not included in the official childhood
of 61% (3 + 1 schedule). Stripped or dotted regions where PCV13 was included in the im
references to color in this figure legend, the reader is referred to the web version of thi
Please cite this article as: A. Fenoll, C. Ardanuy, J. Liñares et al., Serotypes and ge
year prospective surveillance after pediatric PCV13 licensure. The ODIN study,(NIP) and it was only available privately to parents until 2015–
2016, except in two regions, Madrid (June 2010) and Galicia (Jan-
uary 2011) (Fig. 1).
The aim of this study was to perform an in-depth analysis of the
serotype and genotype epidemiology of IPD in adults in Spain. To
that end, we conducted a multicenter study to analyze the current
serotype and genotype distributions, as well as the antibiotic sus-
ceptibility of invasive pneumococci. We also analyzed the relation-
ship between serotypes and clones by clinical presentation of IPD.
2. Materials and methods
This is a prospective multicenter laboratory-based study per-
formed in nine teaching hospitals of six Autonomous Regions in
Spain (August 2010–June 2015). Adult patients (18 years) with
IPD episodes were eligible to participate if they were hospitalized
at the study site for at least 24 h. The study protocol was approved
by the corresponding local ethics committee, and all patients pro-
vided written informed consent. Clinical follow-up was performed
until discharge (or up to 90 days after if incomplete resolution at
discharge) or death.
IPD was defined as the isolation of S. pneumoniae in normally
sterile fluids (blood, cerebrospinal fluid, pleural fluid, ascitic fluid
and others) from a patient with clinical signs/symptoms of infec-
tion. The patient’s age, immune status, and major clinical presenta-
tion (uncomplicated pneumonia, complicated pneumonia,
meningitis, non-focal bacteremia, peritonitis and others) wereion of participating centers. Flags represents the location of different participant
immunization program during the study period, with an estimated vaccine uptake
munization program (uptake around 95%; 2 + 1 schedule). (For interpretation of the
s article.)
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sion or multilobar infiltration was considered as complicated. As
per the Advisory Committee on Immunization Practices (ACIP),
patients were considered immunocompromised when cancer,
HIV infection, chemotherapy, immunosuppressive treatment,
chronic renal disease, nephrotic syndrome, or other causes of
immunosuppression or immunodeficiency were present [10].
Isolates were sent to the Spanish Reference Laboratory for
Pneumococci and serotyped using the Quellung reaction/dot blot
assay [11]. Only one isolate per episode was considered. Molecular
typing was performed by pulsed-field gel electrophoresis (PFGE).
Genomic DNA embedded in agarose plugs was restricted with SmaI
(New England BioLabs), and fragments were separated by PFGE
[12]. PFGE patterns were compared with representative interna-
tional pneumococcal clones of the Pneumococcal Molecular Epi-
demiology Network [12]. Band patterns were visually compared.
Major PFGE patterns were defined as those including >4 isolates.
At least one representative strain of each major PFGE pattern
was analyzed by multilocus sequence typing (MLST) [13]. Allele
numbers and sequence types were assigned using the MLST web-
site [13]. Major lineages were named as clonal complexes (CC),
with the serotype as superscript (e.g., CC3061; clonal complex
306 of serotype 1). Susceptibility was determined by agar dilution
[12]. Isolates with intermediate- or high-level resistance to oral/-
parenteral penicillin, cefotaxime (considering meningitis and
non-meningitis breakpoints), erythromycin and levofloxacin deter-
mined using current Clinical and Laboratory Standards Institute
(CLSI) breakpoints [14] were considered non-susceptible.
Vaccine types (VTs) were considered serotypes included in the
PCV13 and serotype 6C based on previous data [15]. All other ser-
otypes were considered non-vaccine types (NVTs).
Comparisons between proportions were performed using the
v2 test, Fisher’s exact test and the Likelihood ratio test, as neces-
sary. For quantitative variables, since data did not show normality
in the Kolmogorov-Smirnoff test, the Kruskal-Wallis and Mann-
Whitney tests were used as necessary. Statistical analyses wereTable 1
Annual distribution of serotypes causing IPDs in adults (18 years) in Spain (August 2010
Isolates, n (%) 2010/2011 201
Serotypes 1083 191 242
1 46 (4.2) 12 (6.3) 8 (3
3 137 (12.7) 22 (11.5) 27 (
4 27 (2.5) 7 (3.7) 5 (2
5 1 (0.1) 0 (0.0) 0 (0
6A 8 (0.7) 3 (1.6) 2 (0
6B 7 (0.6) 3 (1.6) 1 (0
6Ca 45 (4.2) 11 (5.8) 11 (
7Fa 68 (6.3) 16 (8.4) 20 (
9V 19 (1.8) 2 (1.0) 7 (2
14 43 (4.0) 11 (5.8) 9 (3
18C 10 (0.9) 1 (0.5) 3 (1
19A 92 (8.5) 18 (9.4) 21 (
19F 27 (2.5) 4 (2.1) 10 (
23F 9 (0.8) 2 (1.0) 3 (1
All PCV13 + 6Ca 539 (49.8) 112 (58.6) 127
8 83 (7.7) 12 (6.3) 17 (
11Aa 46 (4.2) 0 (0.0) 10 (
22F 46 (4.2) 7 (3.7) 11 (
9N 38 (3.5) 6 (3.1) 4 (1
12F 35 (3.2) 2 (1.0) 10 (
15A 32 (3.0) 6 (3.1) 9 (3
24F 29 (2.7) 6 (3.1) 5 (2
16F 28 (2.6) 7 (3.7) 4 (1
10A 22 (2.0) 4 (2.1) 4 (1
All Non-PCV13a 544 (50.2) 79 (41.4) 115
Non-PCV13 serotypes (serotypes not included in PCV13 + serotype 6C) individually show
Period 2010/2011: 01/08/2010–1/06/2011; period 2011/2012: 02/06/2011–1/06/2012; p
2014; period 2014/2015:02/06/2014–01/06/2015.
Please cite this article as: A. Fenoll, C. Ardanuy, J. Liñares et al., Serotypes and ge
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cago IL).
Temporal trends of VTs (individually and overall), NVTs (overall,
and individually for the most prevalent) and CCs within serotypes
were calculated by linear/non-linear regression using time as the
independent variable. The model showing the highest ratio R2/
degrees of freedomwas considered. Trends were considered signif-
icant when p-values were 0.05.
3. Results
3.1. Patients, episodes, serotypes and genotypes
Of the 1107 IPDs included during the 5-year study period, 20
were excluded because they not met the eligibility criteria
(24 h of hospitalization); thus, 1087 episodes were evaluable
(see Supplementary material Table S1 for details on recruitment
by hospital and study period). Strains from four episodes were
not available for further studies. Among evaluable cases, 269
(24.7%) occurred in 18–49-year-old patients, 273 (25.1%) in 50–
64-year-old patients, 220 (20.2%) in 64–74-year-old patients, and
325 (29.9%) in patients older than 74. The clinical presentations
were: pneumonia (772, 71.0%) (401 complicated and 371 uncom-
plicated), meningitis (122, 11.2%), non-focal bacteremia (102,
9.4%), peritonitis (34, 3.1%) and other IPDs (57, 5.2%).
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.vaccine.2018.10.
098.
Among the 1084 available isolates, the most common serotypes
were: serotype 3 (12.7%), 19A (8.5%), 8 (7.7%), 7F (6.3%), 1 (4.2%),
6C (4.2%), 11A (4.2%), 22F (4.2%) and 14 (4.0%), accounting for
56% of the total isolates. VT (PCV13 + 6C) accounted for 539 iso-
lates (49.8%). Table 1 shows the serotype distribution by study per-
iod. The percentage of VTs decreased over time (R2 = 0.812,
b = 0.901, p = 0.037). Individually, serotypes 6C (R2 = 0.821,
b = 0.906, p = 0.034) and 7F (R2 = 0.937, b = 0.964, p = 0.007)–June 2015).
1/2012 2012/2013 2013/2014 2014/2015
200 241 209
.3) 13 (6.5) 12 (5.0) 1 (0.5)
11.2) 27 (13.5) 28 (11.6) 33 (15.8)
.1) 6 (3.0) 4 (1.7) 5 (2.4)
.0) 1 (0.5) 0 (0.0) 0 (0.0)
.8) 1 (0.5) 2 (0.8) 0 (0.0)
.4) 0 (0.0) 3 (1.2) 0 (0.0)
4.5) 10 (5.0) 7 (2.9) 6 (2.9)
8.3) 12 (6.0) 13 (5.4) 7 (3.3)
.9) 2 (1.0) 5 (2.1) 3 (1.4)
.7) 11 (5.5) 8 (3.3) 4 (1.9)
.2) 3 (1.5) 1 (0.4) 2 (1.0)
8.7) 20 (10.0) 20 (8.3) 13 (6.2)
4.1) 5 (2.5) 5 (2.1) 3 (1.4)
.2) 2 (1.0) 1 (0.4) 1 (0.5)
(52.5) 113 (56.5) 109 (45.2) 78 (37.3)
7.0) 9 (4.5) 17 (7.1) 28 (13.4)
4.1) 10 (5.0) 15 (6.2) 11 (5.3)
4.5) 5 (2.5) 9 (3.7) 14 (6.7)
.7) 4 (2.0) 10 (4.1) 14 (6.7)
4.1) 3 (1.5) 9 (3.7) 11 (5.3)
.7) 9 (4.5) 6 (2.5) 2 (1.0)
.1) 8 (4.0) 5 (2.1) 5 (2.4)
.7) 6 (3.0) 5 (2.1) 6 (2.9)
.7) 0 (0.0) 8 (3.3) 6 (2.9)
(47.5) 87 (43.5) 132 (54.8) 131 (62.7)
n are those accounting for 2% of total isolates; asignificant time trends (see text).
eriod 2012/2013: 02/06/2012–01/06/2013; period 2013/2014: 02/06/2013–01/06/
notypes of S. Pneumoniae isolates from adult invasive disease in Spain: A 5-
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4 A. Fenoll et al. / Vaccine xxx (xxxx) xxxdecreased over time. NVTs significantly increased over the study
period; individually, the percentage of serotype 11A (R2 = 0.974,
b = 3.543, p = 0.027) increased over time.
The percentage of VT isolates was higher in the area with low
PCV13 pediatric uptake (Barcelona) than in the area with high cov-
erage (Madrid) (53.9% vs. 40.8%, p = 0.001), with differences for ser-
otype 14 (4.8% vs. 1.8%, p = 0.048). Among NVTs, serotypes 8 and
16F were more common in the region with high coverage (16.9%
vs. 3.9%, p < 0.001, and 4.9% vs. 0.8%, p = 0.002, respectively), while
serotype 24F was more common in the region with low uptake













































Grey color in bars represents CC(s) with <10 isolates
Grey color in bars represents CC(s) with <10 isolates
Fig. 2. Clonal composition of major S. pneumoniae serotypes isolated from adults with IP
bars represents CC(s) with <10 isolates.
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isolates) by serotype. In general, there was an association between
CCs and serotype, with the exception of CC3866C,6B,
CC15614,11A,9V,19A,24F, CC23019A,24F,19F and CC638,15A,23B,19F, which
were associated with more than one serotype. Serotypes 3, 8 and
11A had two major CCs each. Although serotype 19A isolates were
genetically diverse, two CCs (CC23019A and CC32019A) accounted
for 54.3% of 19A isolates. The changes in the CCs over the study
period are shown in Supplementary material Table S2.
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A. Fenoll et al. / Vaccine xxx (xxxx) xxx 5The most common serotypes among pneumonia isolates were:
serotypes 3 (15.1%), 8 (9.6%), 19A (9.5%) and 7F (7.7%). VTs caused
53.9% (414 out of 768) of all pneumonia episodes, and 58.9% (235
out of 399) of complicated pneumonia episodes (Supplementary
material Table S3). Serotype 1 was most common among compli-
cated (7.0%) compared to uncomplicated pneumonia (3.0%,
p = 0.01). There were no differences regarding clonal composition
of isolates causing complicated or uncomplicated pneumonia,
except among serotype 3 CCs. There was an association between
CC1803 and complicated pneumonia (50 of 381 complicated pneu-
monia vs. 24 of 359 non-complicated pneumonia, p = 0.003).
Among pneumonia isolates, 0.9% had penicillin minimum inhi-
bitory concentrations (MICs)  4 lg/mL and 2.5% had cefotaxime
MICs  2 lg/mL (non-meningeal breakpoints).
There were 122 meningitis episodes; serotype 3 (9.8%), and ser-
otypes 11A and 19A (7.4% each) were the most common (Supple-
mentary Table S3). VT accounted for 43.4% of meningitis isolates.
Using meningeal breakpoints, penicillin ( 0.12 lg/mL) and cefo-
taxime ( 1 lg/mL) resistance rates were 30.3% and 12.3%,
respectively.
Finally, serotypes 15A (10.8%), 6C (9.8%), 11A (6.9%) and sero-
types 3 and 9N (5.9% each) were the most common among non-
focal bacteremia isolates, with serotypes 11A (14.7%), 6C (8.8%)
and serotypes 7F, 14, 15B, 17F, 19A, 19F and 24F (5.9% each) the
most common among peritonitis episodes. VTs accounted for
35.3% and 38.2% of non-focal bacteremia and peritonitis isolates,
respectively.
By age group, the most common serotypes in young adults
(<50 years) were serotypes 8 (10.4%), 3 (10.1%), 7F (8.6%), 19A
(6.7%), 1 and 14 (5.6% each), and 6C (5.2%); VTs accounted for
53.4% of isolates. In patients 65 years, the most common sero-
types were 3 (13.5%), 8 (5.5%), 19A (7.9%) and 22F (5.4%), while
VT-IPD represented 46.1% of all IPD (Supplementary Table S4).
Regarding immune status, 616 IPD episodes occurred in
immunocompetent patients and 467 in immunocompromised
patients (Supplementary Table S5). Forty-four different serotypes
were found among immunocompetent patients, five of which
accounted for more than 51% of episodes; the number of serotypes
found among immunocompromised patients was similar (40),
eight of which accounted for 50% of episodes. Serotypes 1 (5.8%
vs. 2.1%, p = 0.003), 3 (16.0% vs. 8.1%, p < 0.001), 7F (7.8% vs. 4.3%,
p = 0.018) and 8 (9.3% vs. 5.6%, p = 0.024) were more frequent
among immunocompetent patients, whereas serotypes 10A (3.6%
vs. 0.8%, p = 0.002), 11A (5.8% vs. 3.1%, p = 0.043) and 15A (5.1%
vs. 1.3%, p  0.001) were more frequent among immunocompro-
mised patients. In these two groups, VTs caused 54.7% (337 out
of 616) of IPD in immunocompetent patients and 43.3% (202 out
of 467) in immunocompromised patients.Table 2
Antimicrobial non-susceptibility rates, range, MIC50, and MIC90, of invasive pneumococci co
All isolates (n = 1083) Meningitis (n =
Range MIC50 MIC90 % Range
Penicillin 0.015–4 0.015 1 0.015–4
0.12 – – – 25.9 –
2 – – – 6.7 –
4 – – – 1.1 –
Cefotaxime 0.015–4 0.015 1 0.015–4
1 – – – 12.4 –
2 – – – 2.7 –
Erythromycin 0.12–128 0.12 128 24.9 0.12–128
Levofloxacin 1–64 1 1 2.7 1–2a
Rates of non-susceptibility regarding specific breakpoints for each group are shown in
parenteral penicillin: 4 mg/L; cefotaxime (meningitis): 1 mg/L; cefotaxime (non-men
a Two isolates with MIC = 2 mg/L.
Please cite this article as: A. Fenoll, C. Ardanuy, J. Liñares et al., Serotypes and ge
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Table 2 shows non-susceptibility data. Overall, non-
susceptibility (MIC  0.12 mg/L) was 25.9% [1.1% for parenteral
MIC  4 mg/L)] to penicillin, 24.9% to erythromycin and 2.7% to
levofloxacin. No differences in non-susceptibility were found
between regions with high and low coverage, except for levofloxa-
cin non-susceptibility, with a significantly higher percentage in the
region with high coverage (6.7% vs. 1.1%, p < 0.001), associated with
a higher percentage of serotype 8.
Table 3 shows non-susceptibility rates for serotypes/CCs. Only
12 isolates were non-susceptible to parenteral penicillin (all
MIC = 4 mg/L): seven serotype 19A (all CC320), two 14 (both
CC156), one 9V (CC156), one 6B and one 23F. According to non-
meningitis breakpoints for cefotaxime, 29 (2.7%) isolates (28
MIC = 2 mg/L, one MIC = 4 mg/L) were non-susceptible: 16 sero-
type 19A (eleven CC320, three CC230, one CC156), nine serotype
14 (eight CC156), two 9V (CC156), one 6B and one 23F. Of the
270 isolates resistant to erythromycin, 239 (88.5%) exhibited
MIC  128 mg/L. Serotypes with levofloxacin non-susceptibility
>10% were 9V (21.1%), 8 (19.3%), 23F (11.1%) and 9N (10.5%). Eigh-
teen out of 29 (62.1%) isolates non-susceptible to levofloxacin
belonged to CC63, of which 15 were serotype 8 and three were ser-
otype 15A. Non-susceptibility by serotype within CCs was exam-
ined for three CCs expressing more than one capsule:
CC638,15A,23B,19F, CC15614,11A,9V,19A,24F and CC23019A,24F,19F. Within
CC63, all isolates belonging to serotype 8 were susceptible to peni-
cillin while all serotype 15A were non-susceptible; levofloxacin
non-susceptibility was 78.9% and 10.3% among isolates of sero-
types 8 and 15A, respectively (p < 0.001). Within CC156, ery-
thromycin non-susceptibility was 100% (19A), 25% (9V) and 8%
(14 and 11A), while non-susceptibility to levofloxacin was 33.3%
(9V), 2.7% (14) and 0% (11A and 19A).4. Discussion
This multicenter study presents an overview of serotype and
genotype distribution causing adult IPD in Spain, a country with
regional differences in PCV pediatric uptake. Approximately half
of IPDs in adults were caused by VTs, although the percentage
decreased over the 5-year study period, reflecting herd protection
by pediatric vaccination. Among NVTs, significant increases over
time were found only for serotype 11A (appearing in period
2011/2012). Regarding serotype 8 CC638 decreased and CC538
increased. A recent Canadian study described genetic shifts within
serotypes among isolates collected from children 5 years old
because of the impact of PCV13, and suggested selectivellected from adults (18 years) in Spain (2010–2015) regarding clinical presentation.
122) Pneumonia (n = 768)
MIC50 MIC90 % Range MIC50 MIC90 %
0.015 1 30.3 0.015–4 0.015 1 0.9
– – 30.3 – – – 22.9
– – 4.9 – – – 6.4
– – 2.5 – – – 0.9
0.015 1 12.3 0.015–2 0.015 1 2.5
– – 9.8 – – – 9.6
– – 2.5 – – – 2.5
0.12 128 29.5 0.12–128 0.12 128 21.0
1 1 0.0 1–64 1 1 2.9
bold. Breakpoints for non-susceptibility [oral/meningitis penicillin: 0.12 mg/L;
ingitis): 2 mg/L; erythromycin: 0.5 mg/L; levofloxacin: 4 mg/L].
notypes of S. Pneumoniae isolates from adult invasive disease in Spain: A 5-
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Table 3
Antimicrobial non-susceptibility rates for serotypes and related CCs of S. pneumoniae strains collected from adults (18 years) with IPD in Spain (2010–2015).
Serotype Related CCsa Penicillin Cefotaxime Erythromycin Levofloxacin
6C (n = 45) 44.4/– –/– 66.7 –
CC386 (n = 28) 50.0/– –/– 100 –
8 (n = 83) –/– –/– 22.9 19.3
CC53 (n = 54) –/– –/– – 1.9
CC63 (n = 19) –/– –/– 100 78.9
9 N (n = 38) 5.3/– –/– 2.6 –
CC67 (n = 35) 2.9/– –/– 2.9 –
9 V (n = 19) 47.4/5.3 36.8/10.5 15.8 21.1
CC156 (n = 12) 75.0/8.3 58.3/16.7 25.0 33.3
10A (n = 22) –/– –/– 31.8 –
CC97 (n = 15) –/– –/– 13.3 –
11A (n = 46) 69.6/– 50.0/– 28.3 –
CC156 (n = 30) 100/– 76.7/– 6.7 –
CC62 (n = 14) –/– –/– 71.4 –
14 (n = 43) 95.3/4.7 83.7/20.9 11.6 2.3
CC156 (n = 37) 100/5.4 89.2/21.6 8.1 2.7
15A (n = 32) 90.6/– 9.4/– 90.6 9.4
CC63 (n = 29) 100/– 10.3/– 100 10.3
15B (n = 20) –/– –/– 25.0 –
16F (n = 28) 28.6/– –/– 17.9 –
CC30 (n = 19) 5.3/– –/– 26.3 –
19A (n = 92) 68.5/7.6 50.0/17.4 60.9 1.1
CC230 (n = 29) 100/– 51.7/10.3 65.5 3.4
CC320 (n = 21) 100/33.3 100/52.4 95.2 –
19F (n = 27) 59.3/– 33.3/– 70.4 3.7
23A (n = 20) 10.0/– –/– 60.0 –
CC42 (n = 18) –/– –/– 55.6 –
23B (n = 21) 66.7/– 4.8/– 9.5 –
CC2372 (n = 15) 80.0/– –/– 6.7 –
24F (n = 29) 69.0/– –/– 69.0 –
CC230 (n = 18) 100/– –/– 100 –
35B (n = 18) 50.0/– 22.2/– 5.6 –
Absence of non-susceptible isolates is shown by (–).
a Only CC accounting for 10 isolates are show. Breakpoints for non-susceptibility [oral/meningitis penicillin:  0.12 mg/L; parenteral penicillin:  4 mg/L; cefotaxime
(meningitis):  1 mg/L; cefotaxime (non-meningitis):  2 mg/L; erythromycin:  0.5 mg/L; levofloxacin:  4 mg/L].
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and drug resistance potential related to specific clones [16]. Based
on this, not only the decline in VTs, but also the clonal changes in
our study could be due to the herd effect after PCV13 introduction
for children (only in those cases in which there was an association
with serotypes included in the vaccine). However, explaining
changes as derived from PCV13 uptake in children should be con-
sidered with caution, since PCV7/13 had not been universally
administered for pediatric vaccination in all Spanish geographical
areas, and isolates came from adults. In this sense, the analysis of
isolates from a region with high vaccine uptake (PCV7/13 included
in the pediatric immunization program; estimated uptake >80%)
versus one region with low uptake [PCV7/13 not included by the
period analyzed; estimated uptake = 55% [17] was performed to
explore possible herd effects. Based on our findings, indirect effects
can be inferred, since adult VT-IPDs were significantly less frequent
in the area with high pediatric coverage. It has been reported that
there is a decline in carriage of PCV13 serotypes in 50% of non-
immunized children only in communities where pediatric PCV13
coverage is 75%, [18], which indirectly reduces the burden of
VT-IPD. Finally, the genetic diversity or homogeneity of some ser-
otypes and their variations could be related to changes in the clo-
nal composition. For example, since nearly all serotype 7F strains
belonged to CC191, the decrease in this serotype is associated with
a decrease in the CC191. In contrast, the decrease in serotype 14
could not be related with a genotype, since CC156 isolates could
express different capsular types including non-PCV13 serotypes.
In this study we have shown differences in the serotype compo-
sition in terms of clinical presentation, age and immune status, as
has been previously described. Thus, VTs accounted for more than
a half of pneumonia episodes. Since pneumonia is a major threat inPlease cite this article as: A. Fenoll, C. Ardanuy, J. Liñares et al., Serotypes and ge
year prospective surveillance after pediatric PCV13 licensure. The ODIN study,the adult population, a PCV13 vaccination strategies could reduce
the burden of this disease. In addition, some VTs (serotypes 1, 3,
19A and 7F) were associated with complicated pneumonia as
recently reported in Spain [19,20]. Notably, among pneumonia epi-
sodes due to serotype 3 those caused by CC1803 were more fre-
quent among complicated pneumonia suggesting that other
factors beside capsule are also important in the pathogenesis of
infection. Moreover, with respect to immune status non-invasive
serotypes (11A, 9 N, 15A, 10A) were more frequent among
immunosuppressed patients, suggesting that the impaired
immune system could facilitate the invasiveness of these serotypes
[21]. Furthermore, invasive serotypes were more common among
immunocompetent patients (1, 3, 7F, 8) highlighting the major role
of the capsular polysaccharide in the invasiveness.
Previous studieshave suggested that adultswithhigh-risk condi-
tionsmay not benefit from indirect protection as much as immuno-
competent patients [10,22]. Nevertheless, VTs caused 43.3% IPD in
immunocompromised patients that could take advantage of
PCV13 vaccination until herd protection from pediatric PCV13 is
fully established [23].However, considering our data from the area,
where the proportion of VT-IPDs remains high despite >80% pedi-
atric coverage, a better strategy to reduce the burden of adult IPD
would be to offer a specific PCV13 vaccination program not only to
high-risk adults (as currently done in Spain), but to all persons aged
60 years old. Hence, ACIP recommends that PCV13 is routinely
administered to all adults aged 65 years [24]. Specific vaccination
programs in adults have been suggested, since serotypes causing
IPDs in adults are rarely found in the nasopharynx of children [25].
In line with other studies performed in Spain [11,26], our
results shows that penicillin/erythromycin non-susceptibility is
linked to serotypes 15A, 19A, 6B, 19F and 24F, while levofloxacinnotypes of S. Pneumoniae isolates from adult invasive disease in Spain: A 5-
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A. Fenoll et al. / Vaccine xxx (xxxx) xxx 7non-susceptibility was mainly linked to serotype 8 [27–29]. The
relationship between serotype 8 and levofloxacin-resistance was
previously described associated with the spread of a recombinant
clone 8-ST63 (related to clone Sweden15A-ST63) initially confined
in Madrid area and associated with HIV patients [27,29], that
expanded to other regions [27]. Although the main reservoir of
pneumococci are children, isolates of serotype 8 are rarely found,
neither as colonizers or agents of invasive disease [30]. Notably,
since fluoroquinolones are not used in children, the quinolone-
resistance in CC638 represents a problem strictly in adults. Impor-
tantly, in our study we observed a decrease of CC63 within sero-
type 8, with a significant increase in CC538 (susceptible to
penicillin, erythromycin and levofloxacin). Finally, the continuing
presence of CCs strongly linked to high beta-lactam resistance,
such as CC320 (serotype 19A) and CC156 (serotypes 14, 9V and
11A), is also a concern. However, the percentage of serotype 14
was higher among regions with lower vaccination coverage in chil-
dren (data not shown) [17]. This reinforces the need for high vac-
cination coverage in children to protect the main population
affected, and through the herd effect to protect subjects not tar-
geted by vaccination strategies.
The results of the present surveillance study showed that,
although the percentage of VTs as a cause of IPDs in adults in Spain
is decreasing, it remains high, even in areas where PCV7/13 is
included in the pediatric immunization program. Moreover, this
study shows differences in the serotype distribution as regards
clinical presentation, age or immune status highlighting the role
of capsular type in the pathogenesis of pneumococcal infections.
The main limitation of this study is that it is not a population-
based study which hampered to know the real impact of children
vaccination among the burden of adult IPD. However, our study
analyzes a large pneumococcal series causing IPD in adults allow-
ing us to analyze the serotype composition and vaccine coverage of
IPD in different populations targeted by the current 13-valent con-
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